))
The Latest News and Notes, plus Conversation with Steven Dell, MD
Manage episode 457595572 series 3560279
Content provided by Healio, John Hovanesian, MD, FACS, and Jim Mazzo. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio, John Hovanesian, MD, FACS, and Jim Mazzo or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology.
- Welcome to the Eyeluminaries podcast :02
- Review of episode 29 1:28
- Bausch + Lomb acquires Elios Vision 2:07
- ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00
- Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31
- Intro of Steven Dell, MD 11:20
- You have created markets with new technologies and companies. Can that continue in today’s market? 13:28
- Dell discusses presbyopia market development. 14:11
- You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20
- What technologies are going to be the most important in the future? 20:24
- What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00
- Dell discusses Lindstrom’s Integrated Eye Care Delivery Model. 23:08
- What advice would you give a younger Steven Dell? 27:16
- Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06
- Give us your feedback 34:43
- Thanks 34:51
Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants.
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
We’d love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.
Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.
34 episodes
Share
